Mostrar el registro sencillo del ítem

dc.contributor.authorValenzuela-Faccini N
dc.contributor.authorPoveda-Henao C
dc.contributor.authorFlórez-Navas C
dc.contributor.authorPérez-Garzón M
dc.contributor.authorBoada-Becerra N
dc.contributor.authorMercado-Diaz M
dc.contributor.authorSalcedo P
dc.contributor.authorRobayo-Amortegui H.
dc.date.accessioned2024-10-07T21:38:56Z
dc.date.available2024-10-07T21:38:56Z
dc.date.issued2024
dc.identifier.issn14712466
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85182713732&doi=10.1186%2fs12890-023-02753-5&partnerID=40&md5=ed56a109706012ee7b8c1427776d33b2
dc.identifier.urihttp://hdl.handle.net/10818/61878
dc.description.abstractBackground: The SARS-CoV-2 pandemic resulted in shortages of supplies, which limited the use of extracorporeal membrane oxygenation (ECMO) support. As a contingency strategy, polypropylene (PP) oxygenation membranes were used. This study describes the clinical outcomes in patients on ECMO with PP compared to poly-methylpentene (PMP) oxygenation membranes. Methods: Retrospective cohort of patients in ECMO support admitted between 2020 and 2021. Results: A total of 152 patients with ECMO support were included, 71.05% were men with an average age of 42 (SD 9.91) years. Veno-venous configuration was performed in 75.6% of cases. The PP oxygenation membranes required more changes 22 (63.1%), than the PMP Sorin® 24 (32,8%) and Euroset® 15 (31,9%) (p.0.022). The main indication for membrane change was low oxygen transfer for PP at 56.2%, Sorin® at 50%, and Euroset® at 14.8%. Renal replacement therapy was the most frequent complication with PP membrane in 22 patients (68.7%) Sorin® 25 patients (34.2%), and Euroset® 15 patients (31.9%) (p 0.001) without statistically significant differences in mortality. Conclusion: PP oxygenation membranes was a useful and feasible strategy. It allowed a greater disponibility of ECMO support for critically ill in a situation of great adversity during the SARS-CoV-2 pandemic. © 2024, The Author(s).en
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherBMC Pulmonary Medicinees_CO
dc.relation.ispartofseriesBMC Pulmonary Medicine Vol. 24 N° 1 art. 41
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subject.otherComplicationsen
dc.subject.otherECMOen
dc.subject.otherPoly-methylpentene membranesen
dc.subject.otherPolypropylene membranesen
dc.subject.otherSARS-CoV-2en
dc.titleOutcomes of ECMO support with polypropylene membrane during pandemic times: a retrospective cohort studyen
dc.typejournal articlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.1186/s12890-023-02753-5


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International